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Summary
Open-label, multicenter extended availability program with peginterferon alfa-2a used in combination with ribavirin in patients with
CHC in Poland was analysed. Finally, 572 patients were enrolled. The interim analysis of safety and tolerability was performed in
190 patients whose data were available after 72 weeks of observation. Mean hemoglobin level was 14.8 g/dl and decreased to week
24, then remain stable until the end of therapy and returned to the baseline value. Lekocytes level in week 2 decreased, reach a
plateau in week 8 and return to baseline values at end observation. Similar phenomenon was observed with neutrophils. Platelet
count during the treatment fell gradually in week 8 and remained stable. Reported adverse events requiring PEGASYS® or COPE-
GUS® dose reduction were also analyzed. The most frequent adverse effect leading to the reduction of peginterferon alfa-2a dose was
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INTRODUCTION
I Monotherapy with pegylated interferon
alfa-2a PEGASYS®
The safety and tolerability of pegylated interferon alfa-2a
(PEGASYS®) in monotherapy was assessed in phase 2 and
3 studies with almost 1580 patients included. The analysis
included 995 patients who had received at least one dose
of pegylated interferon alfa-2a and 584 patients treated
with standard interferon alfa-2a. The data concerning
safety were based on the treatment period (up to 48
weeks) and an observation period of at least 8 weeks after
completion of the therapy, whereas adverse effects were
analyzed to week 72. Approximately 30% of patients have
been diagnosed as hepatic cirrhosis or advanced fibrosis.
The reported adverse effects were typical of interferon
therapy, and their incidence was comparable in the
groups treated with pegylated interferon alfa-2a and
standard interferon given 3 × a week therapy. No differ-
ences were observed in the frequency of reported serious
adverse events (SAE). The most frequently reported
adverse effects were flu-like symptoms (analogous to
those observed due to enhanced production of endoge-
nous interferon in response to viral infections). Other
adverse effects included hair loss, psychical disturbances
(irritability, dysphoria, mood disturbances). The adverse
effects were usually mild or moderate in intensity.
The necessity of dose modification because of adverse
effects was also similar.
In the study by Zeuzem et al. [1] the safety of pegylated
interferon alfa-2a and standard interferon alfa-2a in
monotherapy was compared. The necessity of treatment
discontinuation because of adverse effects was noted in
7% of patients treated with pegylated interferon alfa-2a
and 10% of those receiving interferon alfa-2a, while the
necessity of dose modification was comparable in both
groups (19 and 18%).
II Safety and tolerability of combined therapy with
ribavirin
The rate of the treatment discontinuations due to
adverse events was lower in the group of patients treat-
ed with pegylated interferon alfa-2a (5.8% in monothe-
rapy and 7.1% in combination with ribavirin) as com-
pared with standard interferon plus ribavirin (9.7%)
and higher with respect to treatment discontinuations
because of laboratory abnormalities (0.9%, 2.6% and
0.9%, respectively) [2].
Hadziyannis et al. [3] presented the rates of discontinued
24- and 48-week therapies with pegylated interferon alfa-
2a – PEGASYS® and ribavirin combination. It was neces-
sary to discontinue treatment in 5% and 4% of patients
on the 24-week treatment schedule and in 16% and 15%
in the group treated for 48 weeks (the patients received
800 and 1000/1200 mg daily doses of ribavirin, respec-
tively) due to adverse events or laboratory abnormalities.
Reduction or omissions of ≥1 doses of pegylated interfer-
on alfa-2a was necessary in 30% and 26% in the group
treated for 24 weeks (on 800 and 1000/1200 mg daily
doses, respectively) and in 33% and 36% for the patients
treated for 48-weeks (on 800 and 1000/1200 mg, respec-
tively). The incidence of serious adverse events (SAE)
associated with the therapy was 3% and 7% (for 24-week
treatment), and 9% and 10% (for 48-week treatment) [3].
Changes of neutrophil counts both during monothera-
py and combined therapy were comparable, and the
observed decrease slightly more pronounced than in
case of combined therapy with standard interferon
given 3 × a week plus ribavirin. Neutropenia <750,
>500 cells/ml (toxicity level 3) was observed in 22%, and
< 500 cells/ml (grade 4) in 4.7% of patients.
Changes of platelet counts during monotherapy and
combined therapy were comparable, and the observed
decrease slightly more pronounced than in case of com-
bined therapy with interferon 3 × a week plus ribavirin.
Thrombocytopenia <50.000 cells/ml (toxicity level 3)
was noted in 4.9% of patients [4].
Lower incidence of fever, myalgia, chills and depression
was observed in the group treated with pegylated inter-
feron alfa-2a in comparison with interferon adminis-
tered 3 times a week [2]. Reduced ribavirin dose (800
mg/d versus 1000/1200 mg/d) was associated with a
lower incidence of SAE, less frequent necessity of dosage
modifications and less frequent severe decreases of
hemoglobin level.
Manns and al. [5] compared efficacy and safety of pegin-
terferon alfa-2b with ribavirin and interferon alfa-2b
with ribavirin at 514 and 505 patients, respectively. They
found that overall discontinuation rate was similar (14
vs. 13%). Dose decreasing was necessary at 42% and 34%
of patients. Higher rate of neutropenia (18% vs. 8%),
fever, nausea and injection- site reaction was observed in
group treated with peginterferon alfa-2b. Injection- site
reaction may be serious (see case report by Gallelli). [6]
Lindsay and al. [7] performed randomized, double-blind
trial comparing pegylated interferon alfa-2b to interferon
alfa-2b as initial treatment for chronic hepatitis C, con-
cluded that no new adverse events were reported, and the
majority of adverse events and changes in laboratory val-
ues were mild or moderate.
neutropenia (81/185), followed by thrombocytopenia (23/185) (12.4%). Anemia was the most frequent reason of ribavirin dose
reduction. It was noted in 16 patients out of 18, who had the doses reduced because of adverse effects. Only in 5 patients, the dose was
reduced because of depression or anxiety. Combined therapy was generally well-tolerated, preliminary analysis data confirms similar
tolerability profile to that observed in phase III clinical trials.
Key words: chronic hepatitis C • combination therapy with pegylated interferon alfa-2a and ribavirin • safety and tolerability
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Tolerability of pegylated interferon alfa-2a (PEGASYS®)
in patients with liver cirrhosis
The adverse events in patients assigned to pegylated inter-
feron alfa-2a at either dose were typical of those seen with
standard IFN. Adverse effects necessitating dose reduc-
tion were more frequent in the group receiving 180 µg
PEGASYS® than in the group receiving 90 µg dose of the
drug, but the same as for patients receiving standard IFN
therapy. The proportions of patients who had to discon-
tinue the therapy were similar in all groups; no patient
discontinued due to neutropenia, and only two patients
receiving the higher dose of pegylated interferon alfa-2a
were discontinued due to thrombocytopenia [8].
Tolerability of pegylated interferon alfa-2a (PEGASYS®)
in patients with renal failure
In a small open-label PK study the frequency of report-
ed adverse effects increased with the severity of renal
insufficiency. In the group of patients with creatinine
clearance >100 ml/min, adverse effects were reported
in 50% of cases, and in the group with creatinine clear-
ance <40 ml/min – in 100% [9].
III Open-label, multicenter extended availability
program (EAP) with peginterferon-2a (40KD)
(PEGASYS®) used in combination with ribavirin
(COPEGUS®) in patients with chronic hepatitis C
in Poland
Safety and tolerability – study phase summary
To the study 572 patients in total were enrolled accord-
ing to the Roche protocol BV 16209 in 14 centers in the
whole country. Detailed inclusion criteria are given by
Juszczyk et al. [10].
The following interim analysis was performed in 190
patients. 
The patients were monitored according to the approved
study protocol.
The study visits were scheduled for weeks 0, 2, 4, 8, 16, 24,
32, 40, 48 during treatment and follow-up visits for weeks
8 and 24 after the completion of treatment. The moni-
tored safety parameters included blood cell count, bio-
chemical parameters of liver, kidney and thyroid function.
The results of safety parameters assessment after 72
weeks of observation and are currently available in 148 of
163 patients. This group accounts for 78–85% of patients
enrolled in the study and it seems that analysis at this
stage may be useful for the needs of study monitoring.
Table 1 presents the changes of mean hemoglobin levels
during the therapy.
The analysis includes 163 subjects whose complete data
are available. At the baseline, before the treatment,
mean hemoglobin level was 14.8 g/dl. In week 2 from
the start of the therapy, mean hemoglobin value was
14.0 g/dl and decreased to week 24 of treatment when it
reached the level of 12.5 g/dl. That level remained more
or less stable until the completion of the therapy in
week 48. These values differed from the baseline with
statistical significance (p<0.001).
In week 72 of observation, mean hemoglobin levels
returned to the baseline value of 14.7 g/dl.
Table 2 presents the changes of mean leukocyte counts
during the therapy.
The analysis includes 162 subjects whose data were avai-
lable. The mean baseline leukocyte count at the beginning
of treatment was 6.1 (×109/l). In week 2 of the therapy it
decreased to 4.3 (×109/l), reaching in week 8 value of 3.4
(×109/l) slowly decreased until to 3.1 (×109/l) in week 48.
The difference from the baseline was statistically signifi-
cant (p<0.001) Control tests in week 72 of observation
confirmed return of leukocyte count to baseline values at
the level of 5.8 (×109/l).
A similar phenomenon (Table 3) was observed with
respect to neutrophils.
Mean ±standard
deviation
95% confidence
interval
14.8±1.4
(14.6–15.0)
14.0±1.5
(13.8–14.2)
13.2±1.5
(13.0–13.4)
12.9±1.5
(12.6–13.1)
12.6±1.4
(12.4–12.8)
12.5±1.4
(12.2–12.7)
12.6±1.3
(12.4–12.8)
12.5±1.4
(12.3–12.7)
12.6±1.4
(12.4–12.9)
14.7±1.6
(14.4–14.9)
Table 1. Mean hemoglobin levels (g/dl).
Weeks 0 2 4 8 16 24 32 40 48 72
Mean ±standard
deviation
95% confidence
interval
6.1±1.4
(5.9–6.3)
4.3±1.5
(4.0–4.5)
3.7±1.2
(3.5–3.8)
3.4±1.2
(3.2–3.6)
3.3±1.0
(3.1–3.4)
3.3±1.5
(3.0–3.5)
3.2±1.0
(3.1–3.4)
3.1±1.1
(2.9–3.2)
3.1±1.1
(3.0–3.3)
5.8±1.6
(5.6–6.0)
Table 2. Mean leukocyte counts (×109/l).
Weeks 0 2 4 8 16 24 32 40 48 72
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To the analysis were included 148 patients. The baseline
value was 3.2 (×109/l). In week 2, the neutrophil count
decreased to 1.9 (×109/l) reaching a plateau of values rang-
ing from 1.5 a 1.7 (×109/l) by week 4. These differences
were also statistically significant in comparison with the
baseline (p<0.001). After the completion of treatment, in
week 72, the mean neutrophil count was 3.3 (×109/l).
Table 4 analyzes mean platelet counts in 158 patients.
At the beginning of the treatment, the mean value was
198.7×109/l. During the treatment, the platelet counts
fell gradually to the level of 137.3×109/l in week 8 and
remained at that level until the end of the therapy in
week 48. The difference from the baseline was statisti-
cally significant (p<0.001). After the completion of
treatment, mean platelet counts normalized, reaching
the value of 198.1×109/l.
The reported adverse events requiring PEGASYS® or
COPEGUS® dose reduction were also analyzed. Five
patients were excluded from the analysis, because the
dates of completion of their treatment were unknown.
Thus, the analysis included 185 subjects.
It was necessary to reduce (temporarily or permanently)
the dose of interferon in 145 cases (what means that a
dose reduction could take place more than once in a sin-
gle patient case), in 18 cases the reduction of ribavirin was
required. The most frequent adverse effect leading to the
reduction of peginterferon alfa-2a dose was neutropenia
(81/185) (43.8%), followed by thrombocytopenia (23/185)
(12.4%). Anemia was the most frequent reason of ribavirin
dose reduction. It was noted in 16 patients out of 18, who
had the doses reduced because of adverse effects. Only in
5 patients, the dose was reduced because of depression or
anxiety. The data are presented in Table 5.
In the analyzed group of 190 patients, the total number
of reported SAE was 15. None of the SAE occurred
more frequently than in one case. The list of such
adverse events is presented in Table 6.
CONCLUSIONS
• combined therapy with PEGASYS® 180 ug/week/CO-
PEGUS® 800 mg/day administered for 48 weeks was
generally well-tolerated,
Mean ±standard
deviation
95% confidence
interval
3.2±1.0
(3.0–3.4)
1.9±0.9
(1.7–2.0)
1.6±0.8
(1.5–1.7)
1.5±0.7
(1.4–1.6)
1.6±0.6
(1.5–1.7)
1.7±1.4
(1.5–2.0)
1.7±0.8
(1.6–1.8)
1.6±0.8
(1.5–1.7)
1.7±0.9
(1.5–1.8)
3.3±1.2
(3.1–3.5)
Table 3. Mean neutrophil counts (×109/l).
Weeks 0 2 4 8 16 24 32 40 48 72
Mean ±standard
deviation
95% confidence
interval
198.7
±53.9
(190.2
–207.1)
160.3
±48.5
(152.7
–168.0)
149.5
±46.3
(142.2
–156.7)
137.3
±45.5
(130.2
–144.5)
138.3
±50.3
(130.4
–146.2)
143.3
±48.0
(135.8
–150.9)
138.7
±46.2
(131.5
–146.0)
134.5
±43.2
(127.7
–141.3)
137.1
±45.8
(129.9
–144.3)
198.1
±54.7
(189.5
–206.7)
Table 4. Mean platelet counts (×109/l).
Weeks 0 2 4 8 16 24 32 40 48 72
Neutropenia
Thrombocytopenia
Anemia
Elevated AIAT activity
Headache
Asthenia
Depression/anxiety
Hair loss
Others
Total
81
23
1
3
6
7
3/2
1
18
145
1
0
16
0
0
0
0
0
1
18
Table 5. Reported adverse events leading to reduction of drug doses.
Adverse effect type Dose reductionPEGASYS®
Dose reduction
COPEGUS®
Diarrhoea
Hypertension – aggravation
Syncope
Fever
Subarachnoid hemorrhage
Hypothyroidism
Renal carcinoma
Acute gastroenteritis
Tonsillitis
Open left tibia fracture
Thyroiditis
Thyroid adenoma
Thumb injury
Depression
Pregnancy of patient’s wife (healthy offspring)
Total
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
15
Table 6. Reported serious adverse events (SAE).
Adverse effect type Number of cases
16
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• the therapy requires frequent monitoring of blood
parameters, especially leukocyte and thrombocyte
counts. In case of early detection of abnormalities,
dose reduction is sufficient,
• preliminary analysis of EAP – Pegasys program data
confirms similar tolerability profile to that observed in
phase III clinical trials,
• considerably lower depression rates (as compared
with standard therapy) are interesting,
• only 9/190 (4.7%) did not complete the therapy (includ-
ing 3.2% withdrawn because of side effects). According
to literature data, discontinuation rates reach 10–16.1%.
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